whatshot

DNTH   $82.43  -2.89% Market Closed After Close 82.43 0.0

Dianthus Therapeutics, Inc.
show_chart Advanced Chart of DNTH

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 139.36
Mean unverified/preliminary 139.36 / 139.36
Target Price Low / High 122.00 / 200.00
Median / STD DEV 132.50 / 19.87
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell None None
stoch Sell None None
ma20 Sell Sell None
ma50 Sell None None
ma100 Sell Sell Sell
Candlestick PatternOct. 7, 2026 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US2528281080
ceo Mr. Marino Garcia M.B.A.
Website https://dianthustx.com
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.